ExploreWatchlistsPricing
  1. JP-listed companies
  2. AnGes, Inc.
  3. Financials
  4. Pretax margin (%)

AnGes, Inc. (4563)

Market cap
¥22.6B
P/E ratio
-2.2x
AnGes develops gene medicines and nucleic acid treatments, while providing genetic screening tests for rare disorders through its clinical research laboratory.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndPretax margin (%) YoY (%)
Dec 31, 2025-605-48.34%
Dec 31, 2024-1,171.1-68.30%
Dec 31, 2023-3,694-83.04%
Dec 31, 2022-21,786.2+2.84%
Dec 31, 2021-21,183.8+28.02%
Dec 31, 2020-16,546.7+1541.80%
Dec 31, 2019-1,007.8+98.58%
Dec 31, 2018-507.5-43.96%
Dec 31, 2017-905.6-3.92%
Dec 31, 2016-942.6-0.85%
Dec 31, 2015-950.7+261.14%
Dec 31, 2014-263.2-6.50%
Dec 31, 2013-281.5-27.09%
Dec 31, 2012-386.1-47.53%
Dec 31, 2011-735.9

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat